Literature DB >> 30221497

Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.

Yanqiang Wu1, Xianghua Fu1.   

Abstract

BACKGROUND: This study aimed to explore the correlation of baseline, procedural, and postprocedure characteristics with the risk of rapid angiographic stenotic progression (RASP) and restenosis in coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI) with drug-eluting stents implantation.
METHODS: Two hundred fourteen CAD patients underwent PCI with drug-eluting stents implantation were consecutively enrolled. Baseline, procedural, and postprocedure characteristics of patients were collected for analysis. Coronary angiography was performed to evaluate coronary stenosis before PCI and at 12 months after PCI. RASP of nontarget lesions and restenosis of stent-implanted target lesions were then assessed.
RESULTS: 37.8% CAD patients occurred RASP at 12 months after PCI and compared to non-RASP group, RASP group presented with increased diabetes mellitus (DM) complication, higher concentration of serum uric acid (SUA), cardiac troponin I, N-terminal probrain natriuretic peptide, and high sensitive C-reactive protein (hs-CRP) as well as elevated occurrence of multivessel artery lesions. In addition, DM, SUA, hs-CRP, and multivessel artery lesions independently predicted high RASP risk. For restenosis, 21.0% patients occurred restenosis at 12 months after PCI, and patients in restenosis group presented with increased hypertension and DM occurrence, higher concentrations of SUA, LDL-C, and hs-CRP, as well as longer target lesion and length of stent in surgery compared to nonrestenosis group. Also, DM, SUA, LDL-C, hs-CRP, and length of target lesion independently predicted increased restenosis risk.
CONCLUSION: Diabetes mellitus, SUA, and hs-CRP are potential predictive factors for increased risk of both RASP and restenosis in CAD patients underwent PCI and drug-eluting stents implantation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990RASPzzm321990; coronary artery disease; drug-eluting stents; hs-CRP; restenosis

Mesh:

Substances:

Year:  2018        PMID: 30221497      PMCID: PMC6818547          DOI: 10.1002/jcla.22666

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  26 in total

1.  C-reactive protein and rapidly progressive coronary artery disease--is there any relation?

Authors:  Michael N Zairis; Stavros J Manousakis; Alexander S Stefanidis; Denis P Vitalis; Evangelos M Tsanis; Seraphim M Hadjigeorgiou; Constantine N Fakiolas; Evangelos G Pissimissis; Christopher D Olympios; Stefanos G Foussas
Journal:  Clin Cardiol       Date:  2003-02       Impact factor: 2.882

2.  Systemic inflammation after drug-eluting stent placement.

Authors:  Prospero B Gogo; David J Schneider; Matthew W Watkins; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

Review 3.  Consolidated and emerging inflammatory markers in coronary artery disease.

Authors:  Valter Lubrano; Silvana Balzan
Journal:  World J Exp Med       Date:  2015-02-20

Review 4.  Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.

Authors:  Seo Young Kim; James P Guevara; Kyoung Mi Kim; Hyon K Choi; Daniel F Heitjan; Daniel A Albert
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-02       Impact factor: 4.794

5.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.

Authors:  R Kornowski; M K Hong; F O Tio; O Bramwell; H Wu; M B Leon
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

6.  Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus.

Authors:  Rishi Sukhija; Wilbert S Aronow; Ravi Sureddi; Sumith Aleti; Behzad Molavi; Rajesh Sachdeva; Jawahar L Mehta
Journal:  Am J Cardiol       Date:  2007-06-13       Impact factor: 2.778

Review 7.  Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis.

Authors:  Thomas A Trikalinos; Alawi A Alsheikh-Ali; Athina Tatsioni; Brahmajee K Nallamothu; David M Kent
Journal:  Lancet       Date:  2009-03-14       Impact factor: 79.321

8.  Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.

Authors:  Yanqiang Wu; Xianghua Fu
Journal:  J Clin Lab Anal       Date:  2018-09-17       Impact factor: 2.352

9.  Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis.

Authors:  Lin Zhao; Weiwei Zhu; Xiaojiang Zhang; Dongfang He; Chengjun Guo
Journal:  BMC Cardiovasc Disord       Date:  2017-01-06       Impact factor: 2.298

10.  Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation.

Authors:  I-Chang Hsieh; Chun-Chi Chen; Ming-Jer Hsieh; Chia-Hung Yang; Dong-Yi Chen; Shang-Hung Chang; Chao-Yung Wang; Cheng-Hung Lee; Ming-Lung Tsai
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

View more
  7 in total

1.  Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.

Authors:  Yanqiang Wu; Xianghua Fu
Journal:  J Clin Lab Anal       Date:  2018-09-17       Impact factor: 2.352

2.  Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents.

Authors:  Jinling Sun; Hui Yu; Haining Liu; Dongyu Pu; Junhui Gao; Xiaodong Jin; Xiqiang Liu; Aiguo Yan
Journal:  J Clin Lab Anal       Date:  2019-11-14       Impact factor: 2.352

3.  FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.

Authors:  Tingting Song; Yang Fu; Yanbo Wang; Wei Li; Jiayu Zhao; Xun Wang; Haiyan Wang; Ying Zhao; Xianghua Fu
Journal:  BMC Cardiovasc Disord       Date:  2021-01-07       Impact factor: 2.298

4.  Predictive value of inflammatory factors on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis.

Authors:  Xin Chu; Ruzhu Wang; Guixian Song; Xiaohan Jiang
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

5.  Predictive Value of Perioperative Cytokine Levels on the Risk for In-Stent Restenosis in Acute Myocardial Infarction Patients.

Authors:  Dingdao Chen; Xueli Xie; Yinling Lu; Shengli Chen; Sunmei Lin
Journal:  Contrast Media Mol Imaging       Date:  2022-04-23       Impact factor: 3.009

6.  A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients.

Authors:  Qiang Feng; Ying Zhao; Haiyan Wang; Jiayu Zhao; Xun Wang; Jianping Shi
Journal:  Front Cardiovasc Med       Date:  2022-08-11

7.  A prediction model based on platelet parameters, lipid levels, and angiographic characteristics to predict in-stent restenosis in coronary artery disease patients implanted with drug-eluting stents.

Authors:  Min-Tao Gai; Bing Zhu; Xiao-Cui Chen; Fen Liu; Xiang Xie; Xiao-Ming Gao; Xiang Ma; Zhen-Yan Fu; Yi-Tong Ma; Bang-Dang Chen
Journal:  Lipids Health Dis       Date:  2021-09-29       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.